Table 2.
Characteristics of included ongoing studies.
| Clinical trials registration | Status | phase | Center | Location | Intervention | Control | Age range | Sample size |
|---|---|---|---|---|---|---|---|---|
| ChiCTR2200067174 | Recruiting | Phase 4 | Single-center | China | Azvudine + Traditional Chinese medicine | Traditional Chinese medicine | aged 18–65 years | 100 |
| ChiCTR2100052875 | Recruiting | Phase 3 | Single-center | China | Azvudine + standard treatment | Standard treatment | aged 18–60 years | 60 |
| NCT05689034 | Not Yet Recruiting | Phase 2-3 | Multi-center | China | Azvudine | Placebo | 18 years and older | 1096 |
| NCT05682599 | Recruiting | Phase 2 | Single-center | China | Azvudine | Placebo | aged 18–65 years | 300 |
| NCT05633433 | Recruiting | Phase 2-3 | Multi-center | China | Azvudine | Placebo | 18 years and older | 1550 |
| NCT05697055 | Not Yet Recruiting | Phase 4 | Multi-center | China | Azvudine | Paxlovid | 18 years and older | 410 |
| NCT05642910 | Recruiting | NR | Single-center | Malaysia | Azvudine | Paxlovid | aged 18–85 years | 540 |
NR: Not reported.